Corrected: Switzerland's Roivant Q1 loss widens

Roivant Sciences

06/08/2026 12:32

Corrects Adjusted Net Loss number in table to $243.7 mln from 290.61 mln

Overview
Switzerland-based biopharma's Q1 adjusted net loss missed analyst expectations, operating expenses increased
Income from operations and pretax loss for Q1 missed analyst estimates
Company repurchased 7.3 mln shares and received $950 mln from Moderna patent settlement

Outlook
Roivant expects to launch brepocitinib in dermatomyositis by end of September 2026
Company expects topline data from Phase 3 NIU and mosliciguat PH-ILD studies in H2 2026
Roivant says cash position supports runway into profitability

Result Drivers
R&D SPENDING - Higher research and development expenses driven by increased program-specific costs for anti-FcRn franchise and mosliciguat
PERSONNEL COSTS - Increased personnel expenses, including employee bonuses tied to the Moderna settlement, contributed to higher R&D and G&A costs

Company press release: ID:nGNX8F71cV

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
 
$1.44 mln
 
Q1 Adjusted Net Loss
Miss
$243.7 mln
$192.26 mln (4 Analysts)
Q1 Net Loss
 
$290.61 mln
 
Q1 Income From Operations
Miss
-$365.99 mln
-$306.78 mln (7 Analysts)
Q1 Pretax Loss
Miss
$294.56 mln
$243.70 mln (6 Analysts)
Q1 Loss Per Basic Share
 
$0.26
 
Q1 Operating Expenses
 
$367.83 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Roivant Sciences Ltd is $38.00, about 9.8% above its August 5 closing price of $34.60

Reuters Recommended Reads
Aug 3 - Switzerland's CRISPR Therapeutics Q2 CASGEVY revenue jumps 151%, net loss narrows on FDA approval for expansion
Aug 5 - Context Therapeutics Q2 net loss widens on higher R&D costs
Aug 5 - Vaxcyte Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)